Financial Reports: Abbott 3Q12

Abbott 3Q

3Q Revenues: $9.8 billion (-3%)

3Q Earnings: $1.9 billion (3Q11 earnings were $303 million)

YTD Revenues: $29.0 billion (+2%)

YTD Earnings: $4.9 billion (+58%)

Comments: Proprietary pharmaceutical sales dropped 4% in 3Q to $4.4 billion, due to currency fluctuation. U.S. proprietary pharma revenues were up 7% to $2.6 billion. Established pharma revenues dropped 7% to $1.3 billion. For YTD, proprietary pharma revenues were up
2% to $12.9 billion and established pharma revenues down 5% to $3.8 billion. Humira revenues were down 2% to $2.3 billion in the quarter, but up 27% in the U.S. to $1.1 billion. Humira sales YTD were up 6% to $6.6 billion. TriLipix sales rose 4% to $400 million in 3Q and are down 5% YTD at $1.1 billion. 3Q11 earnings were affected by a $1.4 billion legal charge.